Subtopic Deep Dive
Thymoma Classification and Prognosis
Research Guide
What is Thymoma Classification and Prognosis?
Thymoma classification and prognosis involves histopathological systems like WHO and Masaoka-Koga staging for thymic tumors linked to myasthenia gravis, predicting survival and recurrence through multivariate factors.
WHO classification correlates with oncologic behavior, as shown in Okumura et al. (2002, 590 citations) analyzing thymoma histology. Masaoka-Koga staging and invasion predict recurrence per Wright et al. (2005, 244 citations). Over 10 key papers from 1995-2015 establish prognostic models with 200-789 citations each.
Why It Matters
Accurate WHO classification guides surgical resection and adjuvant therapy in thymoma with myasthenia gravis, improving 5-year survival from 70% to 90% in stage I cases (Okumura et al., 2002). Multivariate analyses identify invasion and size as recurrence predictors, informing ESMO guidelines (Girard et al., 2015). Régnard et al. (1996) series of 307 patients links complete resection to 84% 10-year survival, reducing paraneoplastic risks.
Key Research Challenges
Heterogeneity in Classification
WHO and Masaoka-Koga systems show interobserver variability in type B thymomas. Okumura et al. (2002) validated WHO against survival but noted subtype ambiguities. Kondo et al. (2004, 317 citations) confirmed prognostic value yet highlighted diagnostic inconsistencies.
Prognostic Factor Integration
Combining histology, stage, and molecular markers remains inconsistent across cohorts. Blumberg et al. (1995, 402 citations) used multivariate analysis for survival but excluded MG-specific factors. Wright et al. (2005) emphasized invasion over size, needing unified models.
Recurrence Prediction Accuracy
Post-resection recurrence rates vary 10-30% without reliable biomarkers. Régnard et al. (1996) reported 20% recurrence in 307 patients linked to incomplete resection. Girard et al. (2015) guidelines call for better risk stratification in advanced stages.
Essential Papers
Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan
Kazuya Kondo, Yasumasa Monden · 2003 · The Annals of Thoracic Surgery · 789 citations
Myasthenia gravis: recommendations for clinical research standards
Alfred Jaretzki, Richard J. Barohn, Raina M. Ernstoff et al. · 2000 · The Annals of Thoracic Surgery · 636 citations
The World Health Organization histologic classification system reflects the oncologic behavior of thymoma
Meinoshin Okumura, Mitsunori Ohta, Hisashi Tateyama et al. · 2002 · Cancer · 590 citations
Abstract BACKGROUND Although the histologic classification of thymic epithelial tumors has been confusing and controversial, an agreement on the universal classification system for thymic epithelia...
Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Nicolas Girard, Enrico Ruffini, Alexander Marx et al. · 2015 · Annals of Oncology · 481 citations
Prognostic factors and long-term results after thymoma resection: A series of 307 patients
Jean-François Régnard, Pierre Magdeleinat, Christian Dromer et al. · 1996 · Journal of Thoracic and Cardiovascular Surgery · 452 citations
Thymoma: A multivariate analysis of factors predicting survival
David Blumberg, Jeffrey L. Port, Benny Weksler et al. · 1995 · The Annals of Thoracic Surgery · 402 citations
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial
Jinhyun Cho, Hae Su Kim, Bo Mi Ku et al. · 2018 · Journal of Clinical Oncology · 330 citations
PURPOSE Limited treatment options exist for patients with thymic epithelial tumor (TET) whose disease progresses after platinum-based chemotherapy. We conducted a phase II study of pembrolizumab in...
Reading Guide
Foundational Papers
Start with Kondo and Monden (2003, 789 citations) for largest cohort therapy outcomes, then Okumura et al. (2002, 590 citations) for WHO validation, and Régnard et al. (1996, 452 citations) for resection survival baselines.
Recent Advances
Girard et al. (2015, 481 citations) for ESMO guidelines; Cho et al. (2018, 330 citations) on pembrolizumab in relapsed TET; Wright et al. (2005, 244 citations) on recurrence predictors.
Core Methods
WHO histology (types A-B3), Masaoka-Koga staging (I-IV), Cox proportional hazards for multivariate prognosis, Kaplan-Meier survival estimation.
How PapersFlow Helps You Research Thymoma Classification and Prognosis
Discover & Search
Research Agent uses searchPapers for 'thymoma WHO classification prognosis' retrieving Okumura et al. (2002), then citationGraph maps 590 citing papers and findSimilarPapers links to Kondo et al. (2003, 789 citations) for Japanese cohort data.
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival curves from Régnard et al. (1996), verifyResponse with CoVe cross-checks multivariate factors against Blumberg et al. (1995), and runPythonAnalysis computes Kaplan-Meier statistics from abstract data with GRADE grading for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in MG-thymoma prognosis via contradiction flagging between WHO types, while Writing Agent uses latexEditText for staging tables, latexSyncCitations for 10-paper bibliography, and latexCompile for ESMO guideline summaries with exportMermaid for recurrence flowcharts.
Use Cases
"Extract survival data from thymoma resection papers and plot Kaplan-Meier curves"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Régnard 1996, Blumberg 1995) → runPythonAnalysis (pandas survival analysis, matplotlib plots) → GRADE-verified CSV export of 5/10-year survival rates.
"Draft LaTeX review on WHO vs Masaoka-Koga for thymoma prognosis"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Okumura 2002 et al.) → latexCompile → PDF with integrated Masaoka staging diagram.
"Find code for thymoma prognostic models from related papers"
Research Agent → searchPapers 'thymoma prognosis model' → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis on Cox regression scripts linked to Wright et al. (2005) recurrence predictors.
Automated Workflows
Deep Research workflow scans 50+ thymoma papers via searchPapers → citationGraph → structured report on WHO evolution (Okumura 2002 baseline). DeepScan applies 7-step CoVe to verify Girard et al. (2015) guidelines against Régnard (1996) data. Theorizer generates MG-thymoma recurrence hypotheses from multivariate factors in Blumberg et al. (1995).
Frequently Asked Questions
What defines thymoma classification systems?
WHO histologic types A, AB, B1-B3 and Masaoka-Koga stages I-IV classify thymic tumors by epithelial cell morphology and invasion. Okumura et al. (2002) showed WHO reflects survival differences across types.
What are main prognostic methods?
Multivariate Cox models integrate stage, histology, resection status, and size. Blumberg et al. (1995) identified capsular invasion as key survival predictor; Wright et al. (2005) added tumor size.
What are key papers?
Kondo and Monden (2003, 789 citations) analyzed 1,320 patients; Okumura et al. (2002, 590 citations) validated WHO; Régnard et al. (1996, 452 citations) reported 307 resection outcomes.
What open problems exist?
MG-specific prognostic markers and immunotherapy predictors remain unresolved. Girard et al. (2015) guidelines note limited data beyond platinum chemotherapy relapse.
Research Myasthenia Gravis and Thymoma with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Thymoma Classification and Prognosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Myasthenia Gravis and Thymoma Research Guide